|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang P: Epidemiology of lung cancer
prognosis: Quantity and quality of life. Cancer Epidemiology. Verma
M: Humana Press; pp. 469–486. 2009, View Article : Google Scholar
|
|
3
|
Detterbeck FC: Lobectomy versus limited
resection in T1N0 lung cancer. Ann Thorac Surg. 96:742–744. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shih J-Y and Yang P-C: The EMT regulator
slug and lung carcinogenesis. Carcinogenesis. 32:1299–1304. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato M, Shames DS and Hasegawa Y: Emerging
evidence of epithelial-to-mesenchymal transition in lung
carcinogenesis. Respirology. 17:1048–1059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin L and Bivona TG: Mechanisms of
resistance to epidermal growth factor receptor inhibitors and novel
therapeutic strategies to overcome resistance in NSCLC patients.
Chemother Res Pract. 2012:8172972012.PubMed/NCBI
|
|
8
|
Jeon H-S, Lee YH, Lee SY, Jang JA, Choi
YY, Yoo SS, Lee WK, Choi JE, Son JW, Kang YM, et al: A common
polymorphism in pre-microRNA-146a is associated with lung cancer
risk in a Korean population. Gene. 534:66–71. 2014. View Article : Google Scholar
|
|
9
|
Dearth RK, Cui X, Kim H-J, Hadsell DL and
Lee AV: Oncogenic transformation by the signaling adaptor proteins
insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle.
6:705–713. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thomson S, Petti F, Sujka-Kwok I, Epstein
D and Haley JD: Kinase switching in mesenchymal-like non-small cell
lung cancer lines contributes to EGFR inhibitor resistance through
pathway redundancy. Clin Exp Metastasis. 25:843–854. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chung J-H, Rho JK, Xu X, Lee JS, Yoon HI,
Lee CT, Choi YJ, Kim HR, Kim CH and Lee JC: Clinical and molecular
evidences of epithelial to mesenchymal transition in acquired
resistance to EGFR-TKIs. Lung Cancer. 73:176–182. 2011. View Article : Google Scholar
|
|
12
|
Chen J, Han Q and Pei D: EMT and MET as
paradigms for cell fate switching. J Mol Cell Biol. 4:66–69. 2012.
View Article : Google Scholar
|
|
13
|
Hay ED: The mesenchymal cell, its role in
the embryo, and the remarkable signaling mechanisms that create it.
Dev Dyn. 233:706–720. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Denlinger CE, Ikonomidis JS, Reed CE and
Spinale FG: Epithelial to mesenchymal transition: The doorway to
metastasis in human lung cancers. J Thorac Cardiovasc Surg.
140:505–513. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakata S, Sugio K, Uramoto H, Oyama T,
Hanagiri T, Morita M and Yasumoto K: The methylation status and
protein expression of CDH1, p16(INK4A), and fragile histidine triad
in nonsmall cell lung carcinoma: Epigenetic silencing, clinical
features, and prognostic significance. Cancer. 106:2190–2199. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu D, Huang C, Kameyama K, Hayashi E,
Yamauchi A, Kobayashi S and Yokomise H: E-cadherin expression
associated with differentiation and prognosis in patients with
non-small cell lung cancer. Ann Thorac Surg. 71:949–954; discussion
954–945. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hung J-J, Yang M-H, Hsu H-S, Hsu W-H, Liu
J-S and Wu K-J: Prognostic significance of hypoxia-inducible
factor-1α, TWIST1 and Snail expression in resectable non-small cell
lung cancer. Thorax. 64:1082–1089. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tischler V, Pfeifer M, Hausladen S,
Schirmer U, Bonde AK, Kristiansen G, Sos ML, Weder W, Moch H,
Altevogt P, et al: L1CAM protein expression is associated with poor
prognosis in non-small cell lung cancer. Mol Cancer. 10:1272011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhuo WL, Wang Y, Zhuo XL, Zhang YS and
Chen ZT: Short interfering RNA directed against TWIST, a novel zinc
finger transcription factor, increases A549 cell sensitivity to
cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res
Commun. 369:1098–1102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar
|
|
24
|
Friedman RC, Farh KK-H, Burge CB and
Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs.
Genome Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
25
|
Ceppi P and Peter ME: MicroRNAs regulate
both epithelial-to-mesenchymal transition and cancer stem cells.
Oncogene. 33:269–278. 2014. View Article : Google Scholar
|
|
26
|
Park S-M, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive, and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu T, Li J, Yan M, Liu L, Lin H, Zhao F,
Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and -5p
suppress the metastasis of human non-small-cell lung cancer by
downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
Oncogene. 34:413–423. 2015. View Article : Google Scholar
|
|
30
|
Moustakas A and Heldin C-H: Signaling
networks guiding epithelial-mesenchymal transitions during
embryogenesis and cancer progression. Cancer Sci. 98:1512–1520.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou L, Zhao X, Han Y, Lu Y, Shang Y, Liu
C, Li T, Jin Z, Fan D and Wu K: Regulation of UHRF1 by miR-146a/b
modulates gastric cancer invasion and metastasis. FASEB J.
27:4929–4939. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Karakatsanis A, Papaconstantinou I,
Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of
microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c,
miR-221, miR-222, and miR-223 in patients with hepatocellular
carcinoma or intrahepatic cholangiocarcinoma and its prognostic
significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar
|
|
33
|
Xu B, Wang N, Wang X, Tong N, Shao N, Tao
J, Li P, Niu X, Feng N, Zhang L, et al: MiR-146a suppresses tumor
growth and progression by targeting EGFR pathway and in a
p-ERK-dependent manner in castration-resistant prostate cancer.
Prostate. 72:1171–1178. 2012. View Article : Google Scholar
|
|
34
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PLoS One. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carew RM, Browne MB, Hickey FB and Brazil
DP: Insulin receptor substrate 2 and FoxO3a signalling are involved
in E-cadherin expression and transforming growth factor-β1-induced
repression in kidney epithelial cells. FEBS J. 278:3370–3380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Geng Y, Ju Y, Ren F, Qiu Y, Tomita Y,
Tomoeda M, Kishida M, Wang Y, Jin L, Su F, et al: Insulin receptor
substrate 1/2 (IRS1/2) regulates Wnt/β-catenin signaling through
blocking autophagic degradation of dishevelled2. J Biol Chem.
289:11230–11241. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Misra A, Pandey C, Sze SK and Thanabalu T:
Hypoxia activated EGFR signaling induces epithelial to mesenchymal
transition (EMT). PLoS One. 7:e497662012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cui X, Kim H-J, Kuiatse I, Kim H, Brown PH
and Lee AV: Epidermal growth factor induces insulin receptor
substrate-2 in breast cancer cells via c-Jun NH(2)-terminal
kinase/activator protein-1 signaling to regulate cell migration.
Cancer Res. 66:5304–5313. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dearth RK, Cui X, Kim H-J, Kuiatse I,
Lawrence NA, Zhang X, Divisova J, Britton OL, Mohsin S, Allred DC,
et al: Mammary tumorigenesis and metastasis caused by
overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2.
Mol Cell Biol. 26:9302–9314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chan BT and Lee AV: Insulin receptor
substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol
Neoplasia. 13:415–422. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reuveni H, Flashner-Abramson E, Steiner L,
Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M and Levitzki A:
Therapeutic destruction of insulin receptor substrates for cancer
treatment. Cancer Res. 73:4383–4394. 2013. View Article : Google Scholar : PubMed/NCBI
|
